Mouth Ulcers With Crohn's: What the Evidence Says

Mouth ulcers are a recognised part of Crohn's disease. In a nationwide Swiss cohort of 950 people with inflammatory bowel disease, aphthous stomatitis was the second most common extraintestinal manifestation in Crohn's, reported in 10% of patients compared with 4% of those with ulcerative colitis (Vavricka 2011). So no, you are not imagining the connection, and no, it is not a coincidence that the threads asking "anybody else get bad mouth ulcers?" fill up within a day.

What is much less settled is the thing most people actually want to know: does your mouth tell you what your gut is about to do? That is the claim the search results will hand you, usually without a citation, and the evidence behind it pulls in three different directions. One study says oral lesions and bowel inflammation cluster together. Another says they do not track disease activity at all. A third says that oral ulceration in people with IBD is no more common than in people without it.

This article works through all three, separates the genuinely different things that get called a Crohn's mouth ulcer, and is honest about which ones have real treatment evidence. The short version: your own record over several flares is better evidence for you than any of the published studies, and one of the most useful things in this article is a list of what to write down.

Are mouth ulcers actually a Crohn's symptom, or just common?

They are both, and that is the whole difficulty. Roughly one in ten people with Crohn's in the Swiss cohort had aphthous stomatitis recorded by their physician, which put it second only to arthritis among extraintestinal manifestations and ahead of uveitis, erythema nodosum and ankylosing spondylitis at 6% each (Vavricka 2011). That is a physician-completed questionnaire in a large prospective cohort, which is about as good as this kind of prevalence data gets.

Then a 2026 systematic review pooled 21 studies covering 7,791 people, of whom 5,914 had IBD and 1,877 were controls, and found something the patient-facing pages almost never mention. Pooled prevalence of oral ulceration in people with IBD was 20% with a 95% confidence interval of 11% to 33%. Dry mouth came out at 32% (14% to 59%), halitosis 22% (7% to 51%) and tongue changes 11% (4% to 24%). But the comparative analyses showed no statistically significant difference between people with IBD and controls for any of those outcomes, and the authors concluded that the prevalence of oral manifestations does not significantly differ from the general population (Scocca 2026).

Read those confidence intervals again. A pooled dry-mouth estimate spanning 14% to 59% is not a measurement, it is a shrug. The review reports its own risk-of-bias assessment using the Newcastle-Ottawa Scale and calls explicitly for standardised multicentre studies. Its own numbers are the argument for that.

So the honest framing is this. Mouth ulcers are common in Crohn's, and they are common full stop. Recurrent aphthous stomatitis is one of the most frequent oral conditions there is. A single mouth ulcer in someone with Crohn's tells you very little. A pattern of many at once, unusually large ones, ones that take weeks rather than days, or ones that arrive with other changes, tells you considerably more. That difference between the single event and the pattern is why counting matters, and we come back to it below.

Aphthous ulceration sits inside a larger category. An extraintestinal manifestation is inflammation caused by inflammatory bowel disease that turns up somewhere other than the bowel, and the recognised sites are joints, eyes, skin, mouth and bile ducts. These have their own European guideline (Gordon 2024), and we should say plainly that we were not able to read the full text of that guideline for this article, so we cite it only for the fact that dedicated guidance exists. Our guide to joint pain with Crohn's disease carries the shared explainer of what an extraintestinal manifestation is, which ones track bowel activity and which run independently. This article is about the mouth specifically.

Three different things get called a Crohn's mouth ulcer

Most of the confusion in the threads comes from lumping these together. They look different, they are investigated differently, and they respond to different things. The table below has a fourth row, which is the category that is not a Crohn's mouth ulcer at all but gets treated as one for months.

That last row is not theoretical. One of the most instructive threads in r/CrohnsDisease is a person posting a photograph of a "huge painful mouth ulcer" that had been there since Christmas. The top replies, with well over a hundred upvotes between them, all said the same thing: that is not an ulcer, ulcers are openings, this looks like an infection or a cyst, see someone. Several people suggested a mucocele, a ruptured saliva gland sac. The original poster later confirmed it had been biopsied. Two other people in the same thread said they had been treating an identical lesion as an ulcer for months and were going to their dentist because of the discussion (r/CrohnsDisease thread).

What true oral Crohn's looks like, and why it gets missed

Oral Crohn's is not usually a classic canker sore, and that is the single most useful fact in this article. The best evidence comes from a prospective study in Dublin in which every child with suspected inflammatory bowel disease got a systematic dental examination alongside upper endoscopy, colonoscopy and barium follow-through. Of 48 children with Crohn's who were examined by the dentist, 20 had oral Crohn's, which is 41.7% (Harty 2005).

The lesion types are the interesting part. Mucogingivitis, meaning inflammation of the gum and the lining next to it, was the commonest finding at 12 patients. Then mucosal tags in four, deep ulceration in four, cobblestoning in three, lip swelling in three, and pyostomatitis vegetans in one. Non-caseating granulomas, the histological signature of Crohn's, were found in all eight oral biopsies taken. And in two of those children, granulomas were found in the oral biopsy and nowhere else in the entire workup.

Then the line that should be on a poster in every gastroenterology clinic: the consultant gastroenterologists correctly identified the mouth as abnormal in only 9 of the 20 children with oral Crohn's, which is 45%. Children with ulcerative colitis and indeterminate colitis showed only non-specific oral changes.

Two caveats matter before you take 41.7% to your own appointment. This was children at the point of diagnosis, not adults in long-term follow-up, and oral Crohn's is generally more common and more florid in paediatric disease. And it was a dentist doing a systematic exam, which is precisely why the figure is so much higher than the 10% in the Swiss physician-questionnaire cohort. Those two numbers are not in conflict. They are measuring what a dentist finds when looking properly versus what a gastroenterologist records when asking.

There is a related question about where the mouth sits in Crohn's anatomy. Crohn's can affect anywhere from mouth to anus, and upper gastrointestinal involvement is increasingly recognised: in 1,638 people in the Swiss cohort, 6.5% had upper gastrointestinal involvement at diagnosis and 13.1% at any point, with the prevalence at diagnosis rising from 5.1% in 1955 to 1995 up to 11.3% in 2009 to 2016 (Greuter 2018). Reassuringly, upper gastrointestinal involvement did not predict a worse disease course, with a hazard ratio for any complication of 0.887 (95% CI 0.409 to 1.920), and there was a trend towards fewer intestinal fistulas that did not reach significance. That study was funded by the Swiss National Science Foundation and the Swiss IBD Cohort. It is worth knowing because "my Crohn's is in my mouth too" often lands as frightening news, and the data on upper tract involvement does not support that fear.

Do mouth ulcers warn you before a flare? Three studies, three answers

Here is where the popular claim and the evidence part company. The claim, repeated constantly in patient communities and on health sites, is that mouth ulcers are an early-warning sign of a Crohn's flare. The evidence is messier than that, and the messiness is worth understanding.

Study one says they cluster with active disease. A retrospective cohort at Mayo Clinic identified 116 adults with IBD who had presented with at least one oral complaint between 2017 and 2021. Aphthous ulcers were the commonest oral presentation, in 85.1% of those with Crohn's and 75.0% of those with ulcerative colitis. Oral manifestations were associated with Crohn's activity in the small intestine (P = 0.004) and the colon (P less than 0.001), and pancolitis was associated with them in ulcerative colitis (P = 0.002). In 32.7% of patients the oral findings led to an increase in the dose or frequency of IBD therapy, and in a further 16.4% a new systemic agent was started (Loeb 2025).

Three things about that study need saying out loud, because no page quoting it says them.

First, the denominator. Every one of those 116 people was selected because they had an oral complaint. So "85.1% had aphthous ulcers" means 85.1% of oral complaints in people with Crohn's were aphthous ulcers. It does not mean 85% of people with Crohn's get them. Sites that quote it as a prevalence figure have read it wrong.

Second, the definition of "temporal". We read the full text, and the method states that oral manifestations were counted as temporally related to gastrointestinal inflammation if both were active within four weeks of each other. That is a window of simultaneity, and it cannot distinguish the mouth arriving first from the mouth arriving second. A paper whose title promises a temporal relationship therefore does not, on its own method, establish that the mouth warns you.

Third, the proportions in the full text are more sobering than the abstract. Nearly half of the oral findings, 47.4%, were attributed by the treating clinician to the underlying IBD, and 40.5% occurred in association with a flare. Which means roughly three in five oral findings in this cohort of people with IBD and mouth problems were not linked to a flare. We also could not reconcile one figure: the abstract reports 32.7% having therapy escalated plus 16.4% started on a new agent, while the discussion states that "only one-fifth of patients in this study received changes to their IBD treatment." We could not settle which denominator the one-fifth refers to, and we report both numbers rather than picking the more quotable one. The authors also note as a limitation that these patients were not examined by dentists, so other oral manifestations such as periodontitis were probably under-recorded.

Study two says they do not track activity. Twenty-four of 31 children who had oral Crohn's at diagnosis, from the same Dublin group, were followed up for a mean of 55 months. Oral manifestations were still present in 7 of 24, which is 29%. There was no difference in median Paediatric Crohn's Disease Activity Index score between the children who had oral lesions at follow-up and those who did not, and no difference in treatments received or intestinal disease location. The authors concluded that the occurrence of mouth lesions during follow-up "was not a marker for Crohn's disease activity elsewhere in the intestinal tract" (Hussey 2011).

That is a small study, 24 children, and a null result in 24 people is weak evidence for absence. But it is a direct test of exactly the claim in question, and it came out negative. Report it as a negative, because it is one.

Study three says something adjacent that gets over-read. The Swiss cohort found that active disease was independently associated with having an ongoing extraintestinal manifestation in Crohn's, with an odds ratio of 1.95 (95% CI 1.17 to 3.23, P = 0.01), alongside a positive family history at 1.77 (Vavricka 2011). That is genuinely useful, but note the subgroup: it is an odds ratio for any extraintestinal manifestation, not for aphthous stomatitis specifically. The study does not report a separate activity association for mouth ulcers alone. Quoting 1.95 as the odds ratio for mouth ulcers with active Crohn's would be putting a number where the paper does not have one.

Orofacial granulomatosis: the diagnosis nobody mentions

If your problem is swollen lips, a persistently cobbled cheek lining or deep ulcers in the folds of your mouth rather than classic round ulcers, there is a named condition for it and it has its own literature. Orofacial granulomatosis is chronic granulomatous inflammation of the lips, face and mouth. It overlaps with Crohn's without being identical to it, and the overlap pattern is informative.

A systematic review retrieved 507 reported cases of orofacial granulomatosis. Mean age at onset was 23.3 years, with a range from 2 to 89. The commonest features were intraoral mucosal abnormality (49.5%), lower lip swelling (49.1%), upper lip swelling (44.7%) and gum involvement (38.7%). Crohn's disease was present in 93 children under 16 and in 43 adults (Gavioli 2021).

Be careful with the percentages attached to those last two numbers, because they are easy to misread. The review reports 68.3% and 31.9% alongside them, and those are proportions of the 136 cases that had both conditions, not of the 507 cases overall. In other words, of everyone in this review who had both orofacial granulomatosis and Crohn's, about two thirds were children. It does not mean 68% of children with orofacial granulomatosis develop Crohn's. What the review does conclude is that childhood onset carries a higher risk of developing Crohn's, and, importantly for this article, that in most cases the orofacial granulomatosis appeared before the Crohn's.

That is the one place where a clean "the mouth came first" finding exists, and it applies to this specific granulomatous presentation rather than to ordinary aphthous ulcers.

Whether orofacial granulomatosis is a separate disease or a form of Crohn's is genuinely open. A Finnish study recruited 29 young people with orofacial granulomatosis with or without Crohn's, 24 with Crohn's and 20 healthy controls, collected stool for microbiota and calprotectin and saliva for genotyping. The orofacial granulomatosis group showed decreased relative abundance of the class Clostridia and increased Actinobacteria and Bacilli compared with both the Crohn's group and controls, and a NOD2 variant was enriched in orofacial granulomatosis relative to Crohn's. The authors read that as support for orofacial granulomatosis being a distinct phenotype (Höyhtyä 2025).

A larger genetic study pushes in a slightly different direction and is worth quoting precisely because of its subgroup finding. Genotyping 201 patients and 1,023 controls for Crohn's, sarcoidosis and atopy risk variants, a combined analysis of three Crohn's risk variants in NOD2 showed no association with any orofacial granulomatosis subgroup. Rare NOD2 variants were significantly enriched in the group who also had intestinal Crohn's compared with those with mouth disease alone. The conclusion was that NOD2 variants are associated with orofacial granulomatosis only in patients with concurrent intestinal disease (Mentzer 2016, genetics). That study was supported by the Wellcome Trust and the National Institute for Health Research.

The allergy link is striking and comes from the same London tertiary centre. Among 88 patients with orofacial granulomatosis, the prevalence of allergy was 82%, against a general population estimate of 22% (P less than 0.0005). Rates were 39% in Crohn's without oral involvement, and highest of all, 87%, in those with both orofacial granulomatosis and Crohn's. Allergy in ulcerative colitis, at 18%, was no different from population estimates. Within the Crohn's group, allergy was associated with perianal disease but not with disease location in the ileum or colon (Patel 2013). Note that the 22% population figure is an estimate rather than a matched control group measured in the same study, which is a real limitation the authors state.

The cinnamon and benzoate free diet

This is the treatment almost nobody hears about, and it has the most patient-relevant evidence in the whole article. A review of the orofacial granulomatosis literature from 1933 to 2010 found that the commonest sensitivities, mostly identified by patch testing, were to benzoic acid (36%), food additives (33%), perfumes and flavourings (28%), cinnamaldehyde (27%), cinnamon (17%), benzoates (17%) and chocolate (11%). A cinnamon-free and benzoate-free diet was reported to benefit 54% to 78% of patients, with 23% needing no additional therapy at all. Crucially, a positive or negative patch test to cinnamaldehyde or benzoates did not predict who would respond to the diet, and the most concentrated source of benzoate exposure is food preservatives (Campbell 2011). That review lists National Institute for Health Research support.

One inconsistency to note before you quote that range: the same group's later paper describes the diet as "successful in up to 72% of patients", which is not the 78% upper bound in their own review. We could not settle which figure is the intended one, and the difference does not change the practical point.

Two things to hold onto. First, that response range comes from reviewed case series rather than randomised placebo-controlled trials, so some of it will be regression to the mean in a fluctuating condition. Second, this is a specialist dietitian-led exclusion diet in an oral medicine clinic, not a self-started elimination diet. The same group developed a stricter low phenolic acid version and tested it in 10 patients: 7 of 10 responded, with median severity scores improving from week 0 to week 6, and the improvement was maintained in the 5 who completed reintroduction. But the paper states plainly that the diet was nutritionally inadequate for a range of micronutrients and required precautionary supplementation (Campbell 2013). That is the honest reason not to attempt this alone.

One person in the Crohn's threads described being four weeks into topical tacrolimus and one week into a benzoate and cinnamon free diet while the lesion got worse, and being told by another commenter that the diet takes at least six weeks to work (r/CrohnsDisease thread). Whether six weeks is the right number we cannot verify from the published work, which does not report a consistent time to response, but the direction is right: this is not a diet that works in days.

What drug treatment evidence exists for oral involvement

Two findings from the same centre, and both of them split by whether there is gut disease.

Azathioprine was reviewed in 60 of 215 patients with orofacial granulomatosis seen over 12 years, of whom 22 also had Crohn's. Response rates for those with Crohn's plus mouth disease versus mouth disease alone were 54% versus 21% at 4 months (P = 0.03), 59% versus 21% at 12 months (P = 0.003), and 41% versus 24% at 24 months, which was no longer significant (P = 0.16). The factors predicting a need for azathioprine were a diagnosis of intestinal Crohn's, sulcal swelling, sulcal ulcers and upper lip involvement (Mentzer 2016). Note the 24-month column: the difference had faded, and the paper says so.

Anti-TNF therapy was reported in 14 patients, 7 with mouth disease alone and 7 with Crohn's as well. Short-term response was 10 of 14 (71%), falling to 8 of 14 (57%) at one year and 4 of 12 (33%) at two years. Two patients who failed infliximab responded to adalimumab. Oral sulcal involvement predicted response; intestinal Crohn's did not (Elliott 2011). Fourteen people is a case series, described by the authors as the largest reported at the time, which tells you how thin this field is.

Is it the deficiency, the disease or the medication?

All three are plausible and the only way to separate them is a blood test and a conversation, which is exactly why the thread advice to load up on a supplement is the wrong move. The same deficiencies are the ones that turn up in our guide to hair loss with Crohn's disease, and the same reasoning applies there: test before you supplement.

The deficiency evidence is real but smaller than its reputation. In 141 Polish adults, 71 with recurrent aphthous stomatitis and 70 controls, the people with ulcers had anaemia, iron deficiency and B12 deficiency more often than controls, and mean serum iron was significantly lower, although still inside the normal range. Then two counterintuitive findings: the lowest mean serum iron was observed in patients with a mild course of ulceration, and there were no significant differences in mean iron or B12 by the number of lesions per episode. The authors concluded that haematinic deficiencies did not significantly modify the course or clinical phenotype of the condition (Ślebioda 2018).

A meta-analysis of 22 studies found serum iron significantly lower in people with recurrent aphthous stomatitis than in healthy people, with a standardised mean difference of -0.421 (95% CI -0.623 to -0.20) overall (Torabinia 2024). We have to flag something about this paper. Its abstract also prints a zinc estimate of -0.955 with an interval written as (-0.282 to -1.628), with the bounds in reverse order, and a women's iron estimate of -0.483 with an interval printed as (-0.375 to -0373), whose lower bound is above the point estimate and whose upper bound is missing a decimal point. We could not reconcile those two intervals and we are not quoting them. The overall iron figure is internally coherent, so that is the one above.

For zinc there is cleaner work: 19 case-control studies, 1,079 cases and 965 controls, found zinc significantly lower in people with recurrent ulcers, with a weighted mean difference of -21.092 (95% CI -26.695 to -15.490). Heterogeneity was very high at 95.4%, which the authors report, and the association was more pronounced in Chinese populations. A trial sequential analysis indicated the required information size had been surpassed (Al-Maweri 2021). Note that a lower average serum level in a group is not the same as a deficiency in you, and none of this is evidence that supplementing without a measured deficiency helps.

The one randomised trial people will point you to needs its population stated clearly. Sublingual B12 for six months in 58 primary care patients with recurrent aphthous stomatitis reduced outbreak duration, ulcer number and pain, and in the final month more of the treated group reached "no aphthous ulcers" status, reported as 74.1% versus 32.0% (Volkov 2009). Two honest caveats. Those participants were not people with Crohn's disease, so this is evidence about mouth ulcers in general rather than about Crohn's. And the reported percentages cannot be reconciled with the stated group sizes of 31 and 27: 74.1% corresponds exactly to 20 of 27 and 32.0% to 8 of 25, neither of which matches the stated arms. We could not settle that from the abstract.

The deficiency question is not hypothetical in this population. In the Mayo oral manifestations cohort, the most frequent comorbidities were anaemia at 50.9%, nutritional deficiency at 37.1%, anxiety at 36.2% and inflammatory arthritis at 34.5% (Loeb 2025). Half of that group were anaemic. If you have had recurrent mouth ulcers for months and nobody has checked your iron, B12, folate and ferritin, that is a reasonable thing to ask for.

Medication is the third possibility, and it is a question for your team rather than a reason to stop anything. Methotrexate-associated stomatitis has been described in the literature for decades, including a short 1994 report in Arthritis and Rheumatism on managing it (Montecucco 1994). We should be straight that no abstract is available for that paper through PubMed or Europe PMC, so we cite it only for the fact that the phenomenon is documented, and note that it was described in rheumatology patients rather than in people with Crohn's. Going the other way, a systematic review of seven studies covering 1,744 patients (1,477 with Crohn's, 267 with ulcerative colitis) found that both anti-TNF and anti-integrin therapy were followed by a reduction in the prevalence of aphthous stomatitis, with the larger reduction after anti-TNF. The authors themselves offer the likely explanation for that gap: vedolizumab tends to be used in people who did not respond adequately to anti-TNF first, and it is gut-selective, so the two groups were never comparable (Salgado-Peralvo 2022). That is a fair caveat and it means the review cannot be read as a head-to-head. It does fit the many people in the threads who say their ulcers stopped once treatment was working. Nothing here is a reason to start, stop or change any medication: that is a conversation with your IBD team.

There is also a rarer presentation with a name worth knowing, because it is specifically an IBD marker. Pyostomatitis vegetans produces multiple pustules with a distinctive "snail track" appearance in the mouth. A systematic review found 77 published cases with associated IBD, noted that the underlying IBD is not always symptomatic, and stated plainly that no gold standard for management exists and high-level evidence is limited. Recurrence when medication is reduced or stopped is described as considerable (Chrcanovic 2024). It was one of the findings in the Dublin paediatric series too.

The look-alikes that are not Crohn's at all

A Crohn's diagnosis makes clinicians, and patients, attribute everything to Crohn's. Some things in the mouth are not.

Behcet's syndrome. Recurrent oral ulceration is its hallmark, it can involve the gut, and it has its own European management recommendations covering mucocutaneous, joint, eye, vascular, neurological and gastrointestinal involvement (Hatemi 2018). A commenter in one of the mouth ulcer threads told the original poster to "check into Behcet's", and the reply was that their symptoms could look like it and their diagnosis had been uncertain (r/CrohnsDisease thread). That is a fair question to raise with a clinician. It is not something to settle from a forum, and severe mouth ulcers alone do not make it likely.

Coeliac disease. In 97 children with biopsy-confirmed coeliac disease and 31 controls, dental enamel defects were found in 63.9% versus 16.1%, and recurrent aphthous stomatitis in 27.8% versus 22.5%. Ulceration was most prevalent in newly diagnosed, untreated patients at 47%, and showed significant remission on a gluten-free diet (Acar 2026). We would flag that the abstract claims significance for both findings together, and a 27.8% versus 22.5% difference in those group sizes is not something we can verify as significant from the abstract alone. The enamel defect difference is large and clearly real; treat the ulcer comparison with more caution. The clinically useful part is the 47% figure in untreated disease, and the fact that it improved on treatment.

Thrush, herpetic lesions, mucocele, and trauma. All of these appeared in the threads as things people had mistaken for Crohn's ulcers, sometimes for months. A white coating that wipes off is not an ulcer. A recurring fluid-filled swelling in the same spot on a lip or cheek is more likely to be a saliva gland problem. A single ulcer in the same place every time may be catching on a tooth or a filling.

The toothpaste question, and the cinnamon paradox

This is the most actionable, lowest-risk section in the article, and it comes with a contradiction that no consumer page mentions.

A systematic review of four double-blind crossover randomised trials, 124 participants in total with two contributing to the main meta-analysis, found that sodium lauryl sulfate free toothpaste significantly reduced ulcer number, ulcer duration, number of episodes and ulcer pain compared with sodium lauryl sulfate containing toothpaste, and that the direction of effect was consistent across all four trials (Alli 2019). The authors still called for better-designed trials.

But read the largest single trial in that literature. In a double-blind crossover trial of 90 subjects across three comparison groups, with 8 weeks per arm and a 2-week washout, the number of ulcers and the number of episodes did not differ significantly between the sodium lauryl sulfate free and the two containing preparations. Only ulcer duration and mean pain score were significantly reduced during the sodium lauryl sulfate free period (Shim 2012).

So the review says four outcomes improved and the biggest trial in the field says two of those four did not. We cannot tell from the review's abstract which two of the four trials were pooled into the main meta-analysis, so we cannot say whether this trial's null results were inside or outside that pooled estimate. The honest summary for a reader is therefore narrower than the review's conclusion: switching away from sodium lauryl sulfate may make your ulcers hurt less and heal faster, and whether it reduces how often they arrive is unresolved. That is still a reasonable thing to try, because the downside is the cost of a tube of toothpaste.

A long thread in r/CrohnsDisease is built around exactly this. The original poster described years of fine white skin peeling from the inside of their cheeks after brushing, which they had never connected to their toothpaste, and which meant they had been answering "no ulcers" at every clinic appointment (r/CrohnsDisease thread). Whatever the mechanism, that observation is worth more than the theory attached to it: a symptom you have not named is a symptom your consultant never hears about.

Three cautions about that thread, because it also contains the two commonest ways this goes wrong.

And now the paradox. In that same thread, one person reported being told by their dentist that people with Crohn's should use cinnamon toothpaste rather than mint. Several others said they had switched to cinnamon pastes on that advice. Set that against the only dietary intervention in this field with published response rates, which is a cinnamon-free and benzoate-free diet for orofacial granulomatosis, where cinnamaldehyde sensitivity was found in 27% of patients and cinnamon in 17% (Campbell 2011). Cinnamon-flavoured oral products are a recognised cause of oral mucosal reactions. The plausible benign explanation for the dentist's advice is that most cinnamon toothpastes on sale are "natural" brands that happen to be sodium lauryl sulfate free, so the flavour is getting credit that belongs to the missing detergent. One thread commenter worked that out independently. We cannot verify what the dentist actually said or meant, and we are not accusing anyone of anything, but if you have mouth lesions, cinnamon is a strange thing to add on purpose.

Your teeth and gums are part of this, and the evidence is specific

Two findings here, and the subgroup detail matters in both. Our dedicated audit of whether Crohn's affects your teeth goes further into the caries evidence and the dental care side, including what to tell a dentist.

On gum disease, a meta-analysis of longitudinal studies, four on the risk of IBD in people with periodontitis covering over 10 million people and two on the reverse direction covering 33,420, found that periodontitis did not increase the overall risk of IBD (pooled RR 1.04, 95% CI 0.99 to 1.09, P = 0.164). Split by subtype, periodontitis was associated with ulcerative colitis (RR 1.12, 95% CI 1.04 to 1.21) but not with Crohn's disease (RR 0.98, 95% CI 0.92 to 1.04, P = 0.475). Going the other way, people with IBD did have a higher risk of developing periodontitis over time (pooled HR 1.37, 95% CI 1.26 to 1.49), and a trial sequential analysis supported the primary findings (Wang 2024).

That is exactly the kind of result that gets flattened into "gum disease is linked to IBD" on a health page. For Crohn's specifically, the arrow that survived analysis runs one way: having IBD raised the risk of periodontitis, not the reverse. If you have Crohn's, the practical implication is dental follow-up, not guilt about your gums having caused anything.

On tooth decay, a meta-analysis of five studies reported a weighted mean difference in the decayed, missing and filled teeth index of 3.04 between people with IBD and healthy controls, and concluded there is a "remarkably higher" occurrence of caries in IBD (Marruganti 2021). We have to be straight about this one: the abstract reports that difference with a 95% interval of 1.52 to 4.56 and a P value of 0.10, which are contradictory, since an interval excluding zero should not come with a P value of 0.10. It also gives the ulcerative colitis subgroup estimate of 4.01 with the interval 1.52 to 4.56, identical to the overall interval, which cannot be correct as printed. We could not reconcile either and we are not treating the conclusion as settled. Five studies is also a thin base. What survives is a reason to keep up dental appointments, which the broader oral findings support anyway.

Threads about teeth are among the busiest in the Crohn's subreddit, including an 88-comment one on whether Crohn's has affected people's teeth and a separate one titled "Anyone else's dentist not understand???" (r/CrohnsDisease thread). The Mayo cohort's own stated limitation, that its patients were never seen by a dentist, is the same gap from the clinic side.

What treatment evidence exists for the ulcers themselves

Less than you would expect, and being told this is more useful than being handed a confident list.

The Cochrane review of systemic interventions for recurrent aphthous stomatitis included 25 randomised trials, 22 placebo-controlled, assessing 21 different interventions. Only one study was judged at low risk of bias. The conclusion was that there was insufficient evidence to support or refute the use of any intervention, and that this probably reflects poor methodological rigour rather than a true absence of effect (Brocklehurst 2012). The reviewers add a point worth carrying: in practice individual drugs do appear to work for individual patients, and systemic treatment is usually reserved for people who have already failed topical treatment.

Topical steroid paste is the commonest prescription in this space, and the most recent evidence on it is strange. A 2025 systematic review and meta-analysis of 25 randomised trials and 1,474 participants reported that 0.1% triamcinolone acetonide showed no significant advantage over placebo in pain reduction, and no significant difference in healing time versus placebo, while being more effective than several comparators on ulcer size (Al-Zaghruri 2025). The same abstract also contradicts itself: it states in one place that thyme honey was significantly more effective than triamcinolone for pain and ulcer size, and in another that triamcinolone was significantly more effective than thyme honey for ulcer size and healing time. We could not reconcile those two statements and we are not quoting the honey result in either direction. The review's own caution is that there were few placebo-controlled trials and a moderate to high risk of bias.

Two practical readings of that. First, if a prescribed paste helps you, the meta-analysis does not mean it does not, it means the trial literature is too poor to show it. Second, the popularity of an intervention in patient communities is not evidence. The threads recommend lysine, high-dose vitamin C, chlorhexidine mouthwash, salt water, chewable tablets and chemical cautery swabs, largely on the strength of personal experience. For lysine specifically, the only trial we could find in this literature dates from 1994 in a dental journal that we could not open, so we are not citing it and not making a claim about it either way. Anything involving cauterising or cutting a lesion belongs with a clinician.

What to log, and why the count is the useful part

Mouth ulcers are unusual among Crohn's symptoms in one respect: you can see them. That is the thing worth exploiting, and it gets wasted if what reaches your appointment is "I get mouth ulcers sometimes."

Your clinician already has somewhere to put this. The Harvey-Bradshaw Index, the five-item bedside Crohn's activity score, awards one point for mouth ulcers under its complications item, alongside joint pain, eye inflammation, skin lesions, anal fissure, new fistula and abscess (Harvey 1980). Our guide to interpreting a Harvey-Bradshaw Index score goes through what each item is made of and why one point for mouth ulcers sits oddly next to one point for an abscess.

Here is what turns a vague complaint into something usable.

The reason to keep this in one place rather than in your head is the six-month appointment gap. The poster in the toothpaste thread described their consultant asking about ulcers at every visit and answering no each time, because the thing they had was not something they had learned to call an ulcer, and because the thought to mention it only arrived after the appointment was over. Clairop is built for that gap: you can log a symptom in a few seconds by speaking it, and take a summary of the period into your next appointment rather than reconstructing it in the waiting room. Our how it works page shows what that looks like. It is a record, not a diagnosis, and interpreting it is your team's job.

A worked example: two people, eight weeks

Person A, 34, ileocolonic Crohn's, on a biologic for two years. Week one, two ulcers on the side of the tongue, both gone by day nine. Stool three times a day, her normal. Week three, one ulcer, gone in a week. Week five, four ulcers at once, two of them in the fold between her lower lip and gum, the biggest still there at day twelve. In the same week her stool count goes to five, she is exhausted in a way sleep does not fix, and her right knee aches. Week six, six ulcers, no blood, still five stools a day, and she has lost a kilogram without trying.

What she takes to her team is not "my mouth is bad again". It is a count going 2, 1, 4, 6 over six weeks, with two in the sulcus, with healing time going from nine days to over twelve, arriving alongside a rising stool count, new fatigue and a joint. That is a pattern, and it is the kind of pattern the Mayo cohort found clinicians acting on (Loeb 2025). It is also exactly the presentation where her team would reasonably check calprotectin rather than treating the mouth.

Person B, 41, small bowel Crohn's, in remission, no treatment change in three years. He gets one or two ulcers most months, always on the inside of his cheek, always healed inside ten days, and they have done this for as long as he can remember, including through two years of confirmed deep remission. His stool count has not changed. He has never had his ferritin or B12 checked since his last resection.

His pattern is the opposite conclusion. A stable, low, unchanging count that does not move with his gut is much more likely ordinary recurrent aphthous stomatitis, plausibly with a haematinic component worth measuring given his surgical history, than a flare signal. The Dublin follow-up study describes exactly this: mouth lesions that persist without tracking intestinal activity (Hussey 2011). The useful conversation for him is about bloods and about a sodium lauryl sulfate free toothpaste, not about escalating treatment.

Same symptom. Two different meanings. The only thing that separated them was a count with dates on it.

Myths worth retiring

"Mouth ulcers are a reliable early warning that a flare is coming." Not as a general rule. The best recent study defines its temporal window as four weeks of simultaneity in either direction and cannot establish precedence (Loeb 2025), and a direct follow-up study of children with oral Crohn's found later oral lesions were not a marker of intestinal activity at all (Hussey 2011). For an individual, a personal log may show it clearly. For the population, the claim is not established.

"Getting mouth ulcers means your Crohn's is worse than average." In 116 people with IBD and oral complaints, fewer than half the oral findings, 47.4%, were attributed to the underlying IBD, and 40.5% coincided with a flare (Loeb 2025). Upper gastrointestinal involvement in Crohn's, separately, did not predict a worse disease course (Greuter 2018).

"People with IBD get far more mouth ulcers than everyone else." The most recent meta-analysis found pooled oral ulceration at 20% in IBD and no statistically significant difference from controls (Scocca 2026). That is a negative result and it deserves reporting as one, alongside the 10% figure from the Swiss cohort (Vavricka 2011). The two are measuring different things, and neither supports a dramatic claim.

"Take B12 or zinc and they will go away." There is a randomised trial of sublingual B12 showing benefit, but in primary care patients with recurrent ulcers rather than in people with Crohn's, and with percentages we could not reconcile against its own group sizes (Volkov 2009). Lower group-average iron and zinc levels (Torabinia 2024, Al-Maweri 2021) are not the same as a deficiency in you, and one study found the lowest iron levels in the people with the mildest ulceration (Ślebioda 2018). Get measured, then discuss it.

"Steroid paste is proven to work." A 2025 meta-analysis of 25 trials found 0.1% triamcinolone acetonide showed no significant advantage over placebo for pain reduction or healing time, and contradicted itself about its comparators (Al-Zaghruri 2025). The Cochrane review of systemic options found insufficient evidence to support or refute any of 21 interventions, with only one of 25 trials at low risk of bias (Brocklehurst 2012). That is a statement about the trials, not about you: if a prescribed paste helps, keep using it.

"Gum disease causes IBD." Not for Crohn's. Longitudinal meta-analysis found periodontitis associated with ulcerative colitis but explicitly not with Crohn's disease, while IBD did raise the risk of later periodontitis (Wang 2024). Check the subgroup before you repeat an effect size.

"Cinnamon toothpaste is better for Crohn's." We could find no evidence for this and some pointing the other way. Cinnamaldehyde and cinnamon sensitivity were found in 27% and 17% of patients with orofacial granulomatosis, and the dietary treatment with published response rates in that condition is cinnamon-free and benzoate-free (Campbell 2011).

"If a mouth lesion has lasted for months, it is just my Crohn's." Sometimes. Sometimes it is a mucocele, an infection or something that needs a biopsy, and the community correctly said so to someone who had lived with one since Christmas (r/CrohnsDisease thread).

When to see a doctor promptly

Contact your IBD team, GP or dentist promptly if you have any of the following. None of this is a substitute for an assessment by someone who can look in your mouth.

• Any single ulcer or lesion that has not healed within three weeks. This is the one to act on even if everything else is fine, because persistent oral ulceration has causes that include infection and oral cancer.
• A lesion that is not behaving like an ulcer: raised rather than hollow, fluid-filled, growing, bleeding heavily, hard, or in one fixed spot recurring indefinitely.
• Mouth pain that is stopping you eating or drinking. Reduced intake worsens the nutritional problems that are already common in Crohn's, and it is a reason for help rather than something to endure.
• New or increasing blood in your stool, unexplained weight loss, fever, night-time symptoms, or symptoms waking you from sleep. These are red flags in their own right and need a doctor promptly.
• Signs pointing to anaemia: breathlessness on stairs you used to manage, persistent light-headedness, or fatigue that is a clear step down from your normal.
• Symptoms outside the gut arriving together: mouth ulcers plus a red or painful eye, plus new joint pain and swelling, plus a new skin lesion. A cluster is worth reporting even when your bowels feel fine.
• Signs of obstruction if you have Crohn's: worsening cramping abdominal pain, vomiting, a swollen abdomen, and no wind or stool passing. This needs urgent assessment, not a wait-and-see.
• Genital ulcers alongside mouth ulcers, or eye inflammation with them. Raise Behcet's as a question with your team.

Our guides to Crohn's fatigue in remission and nausea after eating with Crohn's cover two of the symptoms that most often arrive alongside a bad mouth, and explaining Crohn's fatigue to people covers the harder social half of it.

The honest bottom line

Mouth ulcers are a real, recognised part of Crohn's disease, reported in about 10% of people in the largest cohort to measure it properly (Vavricka 2011). They are also extremely common in people who do not have IBD, and the most recent meta-analysis could not show a significant difference between the two groups (Scocca 2026). Both of those things are true at once, and any page that gives you only one of them is selling you a cleaner story than exists.

The idea that they warn you before your gut flares is true for some individuals and unproven as a general rule. The study most often cited for it measured whether mouth and bowel were active within four weeks of each other, not which came first (Loeb 2025), and the one study that directly tested whether later oral lesions tracked intestinal activity found that they did not (Hussey 2011). The clean "mouth came first" finding that does exist belongs to orofacial granulomatosis rather than to ordinary ulcers (Gavioli 2021).

What is genuinely actionable is narrower and more useful than the early-warning story. Learn what your lesions actually look like, because true oral Crohn's presents as swollen lips, cobblestoning and sulcal ulceration rather than classic canker sores, and gastroenterologists missed it in 55% of children who had it (Harty 2005). Get your iron, B12 and folate measured rather than guessing. Consider a sodium lauryl sulfate free toothpaste, keeping the fluoride, on the understanding that the evidence supports less pain and faster healing more strongly than fewer ulcers (Alli 2019, Shim 2012). Keep your dental appointments, because having IBD does raise the risk of periodontitis even though periodontitis does not raise the risk of Crohn's (Wang 2024). And count them, with dates, because a count is the one thing you can hand a clinician that they cannot get any other way.

If your lesions are not ordinary ulcers, ask specifically whether you should be seen by oral medicine or a dentist with an interest in this. Orofacial granulomatosis has a specialist dietary treatment with real published response rates and a nutritional risk that requires supervision (Campbell 2011, Campbell 2013), and the drug evidence for oral involvement works better when there is gut disease alongside it (Mentzer 2016). None of that happens if the only thing that reaches the clinic is "I get mouth ulcers sometimes."